ORIGINAL RESEARCH
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention Eric A. Secemsky, MD, MSc; Neel M. Butala, MD, MBA; Uri Kartoun, PhD; Sadiqa Mahmood, BDS, MPH; Jason H. Wasfy, MD, MPhil; Kevin F. Kennedy, MS; Stanley Y. Shaw, MD, PhD; Robert W. Yeh, MD, MSc
Background-—Contemporary rates of oral anticoagulant (OAC) therapy and associated outcomes among patients undergoing percutaneous coronary intervention (PCI) have been poorly described. Methods and Results-—Using data from an integrated health care system from 2009 to 2014, we identified patients on OACs within 30 days of PCI. Outcomes included in-hospital bleeding and mortality. Of 9566 PCIs, 837 patients (8.8%) were on OACs, and of these, 7.9% used non–vitamin K antagonist agents. OAC use remained stable during the study (8.1% in 2009, 9.0% in 2014; P=0.11), whereas use of non–vitamin K antagonist agents in those on OACs increased (0% in 2009, 16% in 2014; P
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention Eric A. Secemsky, MD, MSc; Neel M. Butala, MD, MBA; Uri Kartoun, PhD; Sadiqa Mahmood, BDS, MPH; Jason H. Wasfy, MD, MPhil; Kevin F. Kennedy, MS; Stanley Y. Shaw, MD, PhD; Robert W. Yeh, MD, MSc
Background-—Contemporary rates of oral anticoagulant (OAC) therapy and associated outcomes among patients undergoing percutaneous coronary intervention (PCI) have been poorly described. Methods and Results-—Using data from an integrated health care system from 2009 to 2014, we identified patients on OACs within 30 days of PCI. Outcomes included in-hospital bleeding and mortality. Of 9566 PCIs, 837 patients (8.8%) were on OACs, and of these, 7.9% used non–vitamin K antagonist agents. OAC use remained stable during the study (8.1% in 2009, 9.0% in 2014; P=0.11), whereas use of non–vitamin K antagonist agents in those on OACs increased (0% in 2009, 16% in 2014; P
